Showing results (351-360 of 410) with videos related to
Sort By:
Pageof 41
The Journal of Clinical Endocrinology and Metabolism|August 4, 2023
Association Between Free Fatty Acids and Cardiometabolic Risk in Coronary Artery Disease: Results From the PROMISE StudyDeshan Yuan, Na Xu, Ying Song, et al.Nutrients|February 11, 2023
Prevalence and Prognostic Significance of Malnutrition in Patients with Abnormal Glycemic Status and Coronary Artery Disease: A Multicenter Cohort Study in ChinaTianyu Li, Xiaozeng Wang, Zhenyu Liu, et al.JACC. Cardiovascular Interventions|February 22, 2025
Sirolimus- vs Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis: The SIBLINT-ISR Randomized TrialHaiwei Liu, Yi Li, Guosheng Fu, et al.Journal of the American Heart Association|May 31, 2024
Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed DyslipidemiaXiaozeng Wang, Miaohan Qiu, Zhifeng Cheng, et al.Journal of Diabetes|May 3, 2023
Stress hyperglycemia ratio and long-term prognosis in patients with acute coronary syndrome: A multicenter, nationwide studyGuyu Zeng, Ying Song, Zheng Zhang, et al.Journal of the Society for Cardiovascular Angiography & Interventions|October 3, 2025
Impact of Pre-PCI Activated Clotting Time on Outcomes of Bivalirudin Versus Heparin During Primary PCIMeili Liu, Yi Li, Zhenyang Liang, et al.Journal of the American Heart Association|August 23, 2023
Sex Differences in Clinical Characteristics and Outcomes After Myocardial Infarction With Low Ejection Fraction: Insights From PARADISE-MIXiaowen Wang, Karola S Jering, Maja Cikes, et al.JAMA|March 17, 2015
Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trialYaling Han, Jincheng Guo, Yang Zheng, et al.Thrombosis and Haemostasis|December 11, 2023
Percutaneous Coronary Intervention in Acute Coronary Syndrome with Mild-to-Moderate ThrombocytopeniaYicong Ye, Yongchen Hao, Xiliang Zhao, et al.JACC. Cardiovascular Interventions|September 10, 2025
5-Year Outcomes With a Novel Coronary Sirolimus-Eluting Bioresorbable Scaffold: The NeoVas Randomized TrialKai Xu, Guosheng Fu, Xiaozeng Wang, et al.Pageof 41